Plexus Faces Investors: Growth, Strategy, and Scrutiny on Deck

NEENAH, WI – February 23, 2026 – When the management team of Plexus Corp. (NASDAQ: PLXS) takes the stage for a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, they will be facing an audience eager for answers. The electronics manufacturing services provider arrives in Orlando with a powerful tailwind from its recent quarterly performance, but also with several challenging questions looming over its financial narrative. The presentation, scheduled for 10:25 a.m. Eastern Time, represents a critical opportunity for leadership to frame the company's future and reassure a watchful market.

On the surface, Plexus is riding a wave of success. The company's fiscal first-quarter 2026 results painted a picture of robust health, with net sales hitting $1.07 billion, a 9.6% year-over-year increase that marked the fourth consecutive quarter of sequential growth. Non-GAAP earnings per share of $1.78 surpassed analyst expectations, signaling strong operational execution. However, beneath these headline numbers lies a more complex story of divergent paths within its key business segments, a story investors will expect executives to navigate with clarity and confidence.

A Tale of Two Triumphs and a Challenge

The primary engine of Plexus's recent success has been its performance in the highly regulated and complex Aerospace/Defense and Healthcare/Life Sciences sectors. The Healthcare/Life Sciences division was a standout, posting a massive 24.6% year-over-year increase in net sales, contributing 43.6% of the quarter's total revenue. This surge aligns with the company's strategic focus on partnering with firms in demanding regulatory environments, from life-saving medical devices to advanced diagnostic equipment.

Similarly, the Aerospace/Defense segment grew by a formidable 11.5%, with management indicating that momentum could push its full-year growth beyond the previously targeted 9-12% range. This strength is bolstered by significant new program wins. During the first quarter, Plexus secured 22 new manufacturing programs valued at $283 million in annualized revenue. A staggering $220 million of that new business came directly from the Aerospace & Defense sector, underscoring the company's deepening entrenchment in a market benefiting from rising global defense spending and a technological transformation.

However, this dual-engine growth is contrasted sharply by the performance of the Industrial segment. This division, which still accounts for nearly 40% of revenue, saw its net sales decrease by 3.7%. While management had anticipated the decline, attributing it partly to a specific customer disengagement, the contraction raises important questions for investors. They will be listening intently for management's strategy to stabilize and reignite growth in this crucial segment, and for commentary on whether this weakness is an isolated issue or indicative of a broader softening in industrial demand.

Compounding these concerns is the company's cash flow. Plexus reported a negative free cash flow of $50.6 million for the quarter, a stark reversal from the positive $97.2 million in the prior quarter. The company explained the outflow as a strategic investment in inventory to support upcoming program ramps and increased capital spending. While investing in future growth is a valid strategy, a negative cash flow figure invariably attracts scrutiny. The leadership team will need to provide a convincing roadmap for returning to positive cash generation and detail how these investments will translate into future profitability.

The View from Wall Street

Financial analysts are watching Plexus with a cautiously optimistic eye. The consensus rating on the stock hovers between a "Moderate Buy" and "Buy," with price targets that suggest a modest but positive upside. The high-end target from analysts reaches $220, while the low end sits at $150, reflecting the mix of positive momentum and underlying risks.

Analysts have lauded the impressive market share gains in the Healthcare and Aerospace sectors but have also flagged the Industrial segment's contraction and the negative cash flow as key areas to watch. The company's guidance for the second quarter, with revenue projected between $1.11 billion and $1.15 billion and a potential to exceed its full-year growth target of 9-12%, has been received positively. Yet, the execution risk remains.

Adding another layer to the financial picture is the company's capital allocation strategy. In the first quarter, Plexus repurchased over 150,000 shares for $22.4 million. While share buybacks can signal management's confidence in the stock's value, investors will weigh this use of cash against the simultaneous negative free cash flow and the need for ongoing investment in operations.

Leadership and the Path Forward

The task of articulating this complex narrative will fall to a seasoned leadership team, likely led by President and CEO Todd P. Kelsey. Kelsey, who has been with Plexus since 1994 and has served as CEO for nearly a decade, possesses a deep, ground-up understanding of the company's engineering and manufacturing operations. Alongside CFO Patrick John Jermain, he will be expected to provide a strategic vision that not only celebrates recent wins but also directly addresses the challenges.

The upcoming fireside chat is more than a quarterly update; it is a platform to reinforce the core investment thesis for Plexus. The company has long positioned itself as a premier partner for customers with highly complex products that build a better world, from mission-critical defense systems to life-saving medical technology. Its success hinges on navigating intricate supply chains, demanding regulatory hurdles, and rapid technological change—all areas where it has demonstrated significant expertise.

Investors at the Raymond James conference will be listening for a clear articulation of how Plexus will leverage its strengths in the thriving Aerospace and Healthcare markets to offset weakness elsewhere. They will seek assurance that the current cash burn is a temporary and strategic measure that will fuel future returns. Ultimately, the management team's performance in this forum could be as critical as its operational performance in the factory, shaping market perception and setting the tone for the company's valuation through 2026.